Raymond James Issues Pessimistic Forecast for Avantor (NYSE:AVTR) Stock Price

Avantor (NYSE:AVTRGet Free Report) had its price objective decreased by investment analysts at Raymond James from $29.00 to $26.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Raymond James’ price target suggests a potential upside of 17.57% from the company’s current price.

AVTR has been the topic of a number of other research reports. Barclays lowered their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Avantor in a research note on Thursday, September 26th. UBS Group reaffirmed a “neutral” rating and set a $25.00 target price (down previously from $29.00) on shares of Avantor in a research report on Friday, January 17th. Wells Fargo & Company dropped their price objective on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, October 28th. Finally, Robert W. Baird cut their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $27.38.

Check Out Our Latest Stock Report on Avantor

Avantor Trading Up 1.6 %

Shares of AVTR opened at $22.12 on Tuesday. The business’s 50-day moving average price is $21.45 and its 200 day moving average price is $23.40. The stock has a market capitalization of $15.05 billion, a P/E ratio of 48.08, a P/E/G ratio of 3.51 and a beta of 1.28. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. Avantor has a 1-year low of $19.59 and a 1-year high of $28.00.

Institutional Trading of Avantor

Hedge funds have recently modified their holdings of the company. State Street Corp increased its holdings in Avantor by 58.0% during the 3rd quarter. State Street Corp now owns 22,368,244 shares of the company’s stock valued at $578,666,000 after purchasing an additional 8,206,695 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in Avantor by 653.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 6,174,736 shares of the company’s stock valued at $159,740,000 after acquiring an additional 5,354,678 shares in the last quarter. FMR LLC lifted its position in shares of Avantor by 557.2% during the third quarter. FMR LLC now owns 4,675,283 shares of the company’s stock worth $120,950,000 after purchasing an additional 3,963,912 shares in the last quarter. Janus Henderson Group PLC raised its position in Avantor by 18.2% in the 3rd quarter. Janus Henderson Group PLC now owns 17,692,705 shares of the company’s stock worth $457,710,000 after purchasing an additional 2,719,615 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in Avantor by 146.5% during the 3rd quarter. Principal Financial Group Inc. now owns 2,628,372 shares of the company’s stock worth $67,996,000 after buying an additional 1,562,018 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Company Profile

(Get Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

Further Reading

Analyst Recommendations for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.